Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Cantor Fitzgerald
Argus Health
US Department of Justice
US Army
Covington
McKinsey
Merck

Generated: July 18, 2018

DrugPatentWatch Database Preview

Dr Reddys Labs Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DR REDDYS LABS INC, and when can generic versions of DR REDDYS LABS INC drugs launch?

DR REDDYS LABS INC has forty approved drugs.

There are five US patents protecting DR REDDYS LABS INC drugs. There are two tentative approvals on DR REDDYS LABS INC drugs.

There are ninety-three patent family members on DR REDDYS LABS INC drugs in forty-eight countries and eighty-three supplementary protection certificates in thirteen countries.

Summary for Dr Reddys Labs Inc
International Patents:93
US Patents:5
Tradenames:33
Ingredients:25
NDAs:40

Drugs and US Patents for Dr Reddys Labs Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Inc AMOXIL amoxicillin FOR SUSPENSION;ORAL 062226-002 Approved Prior to Jan 1, 1982 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Inc FINASTERIDE finasteride TABLET;ORAL 076436-001 Jul 28, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Inc FLUCONAZOLE fluconazole TABLET;ORAL 076658-004 Jul 29, 2004 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Inc SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 090495-001 Jan 29, 2014 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DR REDDYS LABS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 1000 mg/62.5 mg ➤ Subscribe 2009-01-21

Non-Orange Book US Patents for Dr Reddys Labs Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin ➤ Try a Free Trial
6,660,299 Modified release pharmaceutical formulation comprising amoxycillin ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Dr Reddys Labs Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00375 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
00172 Netherlands ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402
C0033 France ➤ Try a Free Trial PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
00569 Netherlands ➤ Try a Free Trial PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Department of Justice
Boehringer Ingelheim
Fish and Richardson
Chubb
Deloitte
US Army
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.